Curaleaf Holdings (CURLF) EBIT (2019 - 2026)
Curaleaf Holdings (CURLF) posted quarterly EBIT of $753000.0 for Q1 2026, down 91.96% year-on-year from $9.4 million in Q1 2025, and down 92.69% on a QoQ basis from $10.3 million in Q4 2025.
Curaleaf Holdings (CURLF) EBIT (2019 - 2026) Analysis & Trends
Curaleaf Holdings (CURLF) has reported EBIT for 8 consecutive years, with $753000.0 the latest figure, recorded in Q1 2026.
- Quarterly EBIT fell 91.96% year-over-year to $753000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $18.4 million (down 14.15% YoY) and the FY2025 annual result came in at $25.4 million, up 2.86% from the prior year.
- EBIT declined to $753000.0 in Q1 2026 per CURLF's latest filing, from $10.3 million in the prior quarter.
- Over the last five years, EBIT for CURLF reached as high as $43.7 million in Q1 2022 and fell as low as -$81.5 million in Q4 2022.
- A 5-year average of $5.8 million and a median of $7.5 million in 2024 frame the typical range for EBIT.
- Annual changes were most pronounced in 2024 — EBIT sank 34001.34% — and 2025, when it surged 73636.42%.
- Year by year, EBIT stood at -$81.5 million in 2022, then jumped by 100.02% to $13967.0 in 2023, then plunged by 34001.34% to -$4.7 million in 2024, then surged by 317.7% to $10.3 million in 2025, then tumbled by 92.69% to $753000.0 in 2026.
- According to Business Quant data, EBIT over the past three periods registered $753000.0, $10.3 million, and $4.0 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBIT (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 87.22 Bn | 85.35 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 39.60 Bn | 35.87 Bn | 1.97 Bn | 652.00 Mn |
| 3 | Zoetis | 31.46 Bn | 29.52 Bn | 1.62 Bn | 833.00 Mn |
| 4 | Takeda Pharmaceutical | 26.49 Bn | 22.44 Bn | 4.39 Bn | -2.65 Bn |
| 5 | United Therapeutics | 23.03 Bn | 20.88 Bn | 648.10 Mn | 325.80 Mn |
| 6 | Universe Pharmaceuticals | 23.03 Bn | -10.56 Bn | - | - |
| 7 | Viatris | 20.90 Bn | 19.09 Bn | 1.16 Bn | -79.70 Mn |
| 8 | Neurocrine Biosciences | 17.50 Bn | 16.19 Bn | 800.70 Mn | 193.40 Mn |
| 9 | Elanco Animal Health | 12.33 Bn | 11.91 Bn | 785.00 Mn | 291.00 Mn |
| 10 | Curaleaf Holdings | 7.13 Bn | 7.13 Bn | 157.29 Mn | 753,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 753,000.00 |
| Dec 31, 2025 | 10.31 Mn |
| Sep 30, 2025 | 4.03 Mn |
| Jun 30, 2025 | 3.29 Mn |
| Mar 31, 2025 | 9.37 Mn |
| Dec 31, 2024 | -4.74 Mn |
| Sep 30, 2024 | 9.23 Mn |
| Jun 30, 2024 | 7.55 Mn |
| Mar 31, 2024 | 12,702.00 |
| Dec 31, 2023 | 13,967.00 |
| Sep 30, 2023 | 15.21 Mn |
| Jun 30, 2023 | -4.28 Mn |
| Mar 31, 2023 | 17.98 Mn |
| Dec 31, 2022 | -81.53 Mn |
| Sep 30, 2022 | 32.51 Mn |
| Jun 30, 2022 | 35.10 Mn |
| Mar 31, 2022 | 43.73 Mn |
| Dec 31, 2021 | 10.49 Mn |
| Sep 30, 2021 | 41.60 Mn |
| Jun 30, 2021 | 53.37 Mn |